Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)-MedSci.cn

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)

Cheng, Y; He, Y; Li, W; Zhang, HL; Zhou, Q; Wang, B; Liu, C; Walding, A; Saggese, M; Huang, X; Liu, Y; Su, R; Ramalingam, SS

ANNALS OF ONCOLOGY, 2020; 31 (): S838

科室
- - 订阅+
  - 更多科室
工具
服务